Although anti-TNF-α agents are effective in the treatment of PsA, their use has been recognized as a risk factor for active tuberculosis development in patients with immune-mediated inflammatory diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn’s disease, PsA, and psoriasis [16, 17]. This evidence concerns the gene TNF and tuberculosis.